Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas

Acetylsalicylic acid (ASA) is known as a cancer preventing agent, but there is no data available regarding the effect of ASA on pituitary cells. We investigated 66 nonfunctioning (NFPA) and growth hormone (GH)-producing adenomas and 15 normal pituitary samples. Functional assays (cell viability, proliferation, flow cytometry cell cycle analysis, caspase-3 activation and DNA degradation) were applied to explore the effect of ASA, YM155 (survivin inhibitor), survivin-targeting siRNA and TNF-related apoptosis-inducing ligand (TRAIL) in RC-4B/C and GH3 cells. Pituitary adenoma xenografts were generated in immunocompromised mice. We found that survivin was overexpressed and TRAIL was downregulated in NFPAs compared to normal pituitary tissue. ASA decreased proliferation but did not induce apoptosis in pituitary cells. Additionally, ASA treatment decreased cells in S phase and increased cells in G2/M phase of the cell cycle. Inhibition of survivin using an inhibitor or siRNA-mediated silencing reversed the ASA-induced growth inhibition partially. In addition, we also found survivin-independent effects of ASA on the cell cycle that were mediated through inhibition of cyclin A, cyclin dependent kinase 2 (CDK2) and phospho-CDK2. We also aimed to test the effect of acetylsalicylic acid in an animal model using RC-4 B/C cells, but in contrast to GH3 cells, RC-4 B/C cells failed to adhere and grow a xenograft. We concluded that ASA inhibited the growth of pituitary adenoma cells. Survivin inhibition is a key mechanism explaining its antineoplastic effects. Our results suggest that inhibition of survivin with small molecules or ASA could serve as potential therapeutic agents in NFPA.

[1]  Xinqi Cheng,et al.  Survivin overexpression is potentially associated with pituitary adenoma invasiveness , 2017, Oncotarget.

[2]  Ji Ma,et al.  The anti-tumor effect of aspirin: What we know and what we expect. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  I. Kovalszky,et al.  Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas , 2017, Pathology & Oncology Research.

[4]  M. Korbonits,et al.  Novel Genetic Causes of Pituitary Adenomas , 2016, Clinical Cancer Research.

[5]  S. Dubey,et al.  Survivin: a unique target for tumor therapy , 2016, Cancer Cell International.

[6]  L. Pignataro,et al.  Pituitary apoplexy: considerations on a single center experience and review of the literature , 2016, Journal of Endocrinological Investigation.

[7]  S. Asa,et al.  The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas , 2015, Endocrine Pathology.

[8]  G. Vargas,et al.  Pituitary apoplexy in nonfunctioning pituitary macroadenomas: a case-control study. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[9]  R. Spitale,et al.  Molecular targets of aspirin and cancer prevention , 2014, British Journal of Cancer.

[10]  M. Korbonits,et al.  Epidemiology and etiopathogenesis of pituitary adenomas , 2014, Journal of Neuro-Oncology.

[11]  D. Altieri.  Targeting survivin in cancer. , 2013, Cancer letters.

[12]  A. Jankowska,et al.  Survivin--prognostic tumor biomarker in human neoplasms--review. , 2012, Ginekologia polska.

[13]  P. Igaz,et al.  Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. , 2010, The Journal of clinical endocrinology and metabolism.

[14]  B. Sarcevic,et al.  Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. , 2010, Bioscience reports.

[15]  D. Desiderio,et al.  Signaling pathway networks mined from human pituitary adenoma proteomics data , 2010, BMC Medical Genomics.

[16]  F. Zipp,et al.  Bilateral stroke following pituitary apoplexy , 2009, Journal of Clinical Neuroscience.

[17]  G. Giaccone,et al.  Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Jankowska,et al.  Coexpression of survivin and PCNA in pituitary tumors and normal pituitary. , 2009, Neuro endocrinology letters.

[19]  A. Jankowska,et al.  Survivin products in pituitary tumors. , 2008, Neuro endocrinology letters.

[20]  J. Bosman,et al.  Aspirin Sensitizes Cancer Cells to TRAIL–Induced Apoptosis by Reducing Survivin Levels , 2008, Clinical Cancer Research.

[21]  Yong J. Lee,et al.  Aspirin Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Hormone-Refractory Prostate Cancer Cells through Survivin Down-Regulation , 2007, Molecular Pharmacology.

[22]  E. Laws,et al.  CLINICAL RELEVANCE OF PRECIPITATING FACTORS IN PITUITARY APOPLEXY , 2007, Neurosurgery.

[23]  S. Hatakeyama,et al.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.

[24]  Jieun Park,et al.  Nuclear interaction of Smac/DIABLO with Survivin at G2/M arrest prompts docetaxel-induced apoptosis in DU145 prostate cancer cells. , 2006, Biochemical and biophysical research communications.

[25]  T. Griffith,et al.  Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. , 2006, Journal of pediatric surgery.

[26]  A. Jankowska,et al.  Survivin expression in pituitary adenomas. , 2005, Neuro endocrinology letters.

[27]  S. Melmed,et al.  Pathophysiology of pituitary adenomas. , 2005, Journal of endocrinological investigation.

[28]  S. Melmed,et al.  2004 World Health Organization classification of pituitary tumors: what is new? , 2005, Acta Neuropathologica.

[29]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Green,et al.  Aspirin induces apoptosis through release of cytochrome c from mitochondria. , 2000, Neoplasia.

[31]  E. Montserrat,et al.  Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. , 1998, Blood.

[32]  B. Rigas,et al.  Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. , 1996, Experimental cell research.